« Previous
Next »
Titles
- Aducanumab for Alzheimer’s disease: effectiveness and value1
- Alternative pricing models for remdesivir and other potential treatments for COVID-191
- Digital health technologies as an adjunct to medication assisted therapy for opioid use disorder: final evidence report and meeting summary1
- Lecanemab for early Alzheimer’s disease: final evidence report1
- Mavacamten for hypertrophic cardiomyopathy: effectiveness and value : final evidence report and meeting summary1
- Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: effectiveness and value : final evidence report1
- Special assessment of outpatient treatments for COVID-19: final evidence report and meeting summary1
- Special assessment of outpatient treatments for COVID-19: nirmatrelvir/ritonavir (Paxlovid) health-benefit price benchmark update1